140
Views
2
CrossRef citations to date
0
Altmetric
Review

Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence

Pages 547-557 | Accepted 10 Dec 2008, Published online: 15 Jan 2009
 

ABSTRACT

Background: Interferon beta (IFNβ) is a disease-modifying therapy for multiple sclerosis (MS). Although clinical benefits have been demonstrated in several large, randomized, double-blind studies, the optimal dosing of IFNβ is controversial.

Methods: A search was conducted using the key words IFNβ, multiple sclerosis, Avonex, Rebif, Betaseron/Betaferon, efficacy, MRI, and dose–response relationship in MEDLINE, EMBASE, and other databases to locate relevant pivotal clinical trials, other prospective studies, and systematic reviews evaluating the efficacy and tolerability of IFNβ published between 1985 and 2007. This review summarizes the findings of these studies with regard to defining the value of high-dose, high-frequency (HDHF) IFNβ regimens.

Review Summary: All IFNβ formulations and dosages have demonstrated efficacy in well-designed phase 3 trials. Two head-to-head trials suggesting that HDHF regimens result in increased efficacy contained shortfalls in study design that precluded definitive conclusions.

Conclusion: Defining the optimal dose and frequency strategy for IFNβ in patients with MS is complicated by the differences in dosage, route, and frequency of administration among the various agents. Results of well-controlled pivotal trials do not suggest that HDHF IFNβ regimens provide better long-term benefits for patients with MS than low-dose or low-frequency regimens. In addition, HDHF therapies may increase the incidence of side-effects and neutralizing antibodies that reduce efficacy over time. Although the two head-to-head comparisons of different IFNβ therapies found HDHF regimens to be more efficacious than lower-dose/lower-frequency regimens, the design limitations of these studies must be considered when weighing the potential value of the findings for recommending treatment strategies.

Acknowledgments

Declaration of interest: Development of this manuscript was supported by Biogen Idec, Inc. S. M. F. serves on speakers’ bureaus for Biogen Idec, Boehringer-Ingelheim, GlaxoSmithKline, and Pfizer. The author thanks Sabrina Maurer and Matthew Hasson of Scientific Connexions, Newtown, PA, USA for editorial and copyediting assistance in preparing this manuscript.

Notes

* Rebif is a registered trademark of Ares-Serono, Geneva, Switzerland

† Betaseron is a registered trademark of Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA

‡ Avonex is a registered trademark of Biogen Idec, Inc., Cambridge, MA, USA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.